Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
暂无分享,去创建一个
Paul M. Ridker | Nir Barzilai | P. Ridker | M. Alderman | N. Barzilai | S. Rajpathak | J. Crandall | Jill Crandall | D. Kumbhani | Swapnil N. Rajpathak | Dharam J. Kumbhani | Michael Alderman
[1] J. Sasaki,et al. Statins: beneficial or adverse for glucose metabolism. , 2006, Journal of atherosclerosis and thrombosis.
[2] Thomas R Fleming,et al. Identifying and addressing safety signals in clinical trials. , 2008, The New England journal of medicine.
[3] M. Nakata,et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control , 2006, Diabetologia.
[4] P. Ridker. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. , 2007, Journal of the American College of Cardiology.
[5] M. Nakata,et al. Inhibition by simvastatin, but not pravastatin, of glucose‐induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L‐type Ca2+ channels in rat islet β‐cells , 1999, British journal of pharmacology.
[6] P. Libby,et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.
[7] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[8] H. Shimano,et al. Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. , 2006, Journal of atherosclerosis and thrombosis.
[10] K. Ichihara,et al. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. , 2003, Biological & pharmaceutical bulletin.
[11] P W Macfarlane,et al. Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study , 2001, Circulation.
[12] A. Keech,et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. , 2003, Diabetes care.
[13] C. Begg,et al. Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.
[14] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[15] Sarah Parish,et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.
[16] A R Jadad,et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.
[17] R. Collins,et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.
[18] M. Clearfield. Rosuvastatin in older patients with systolic heart failure. , 2009, Current atherosclerosis reports.
[19] L. Chamberlain. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3‐L1 adipocytes , 2001, FEBS letters.
[20] T. Kubota,et al. Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia. , 2006, Internal medicine.